Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
McKesson
Federal Trade Commission
Fuji
Citi
Colorcon
Deloitte
AstraZeneca

Generated: December 11, 2018

DrugPatentWatch Database Preview

AMIKACIN SULFATE Drug Profile

« Back to Dashboard

When do Amikacin Sulfate patents expire, and when can generic versions of Amikacin Sulfate launch?

Amikacin Sulfate is a drug marketed by Abbott, Emcure Pharms Ltd, Fresenius Kabi Usa, Hospira, Igi Labs Inc, Sagent Pharms, Teva Pharms Usa, and West-ward Pharms Int. and is included in twenty NDAs.

The generic ingredient in AMIKACIN SULFATE is amikacin sulfate. There are fifteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the amikacin sulfate profile page.

Drug patent expirations by year for AMIKACIN SULFATE
Pharmacology for AMIKACIN SULFATE
Medical Subject Heading (MeSH) Categories for AMIKACIN SULFATE
Synonyms for AMIKACIN SULFATE
(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-(3-amino-3-deoxy-alpha-D-glucopyranosyloxy)-4-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-3-hydroxycyclohexyl]-2-hydroxybutanamide
(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-(3-amino-3-deoxy-alpha-D-glucopyranosyloxy)-4-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-3-hydroxycyclohexyl]-2-hydroxybutanamide disulfate
(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide; sul
(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxy-tetrahydropyran-2-yl]oxy-3-hydroxy-cyclohexyl]-
(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-{[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-{[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy}-3-hydroxycyclohexyl]-2-hydroxybutanamide
(2S)-4-amino-N-{(1R,2S,3S,4R,5S)-5-amino-2-[(3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy]-4-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-3-hydroxycyclohexyl}-2-hydroxybutanamide
(2S)-4-Amino-N-{(1R,2S,3S,4R,5S)-5-amino-2-[(3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy]-4-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-3-hydroxycyclohexyl}-2-hydroxybutanamide sulfate (1:2)
(2s)-N-[(1r,2s,3s,4r,5s)-4-[(2r,3r,4s,5s,6r)-6-(Aminomethyl)-3,4,5-Tris(Oxidanyl)oxan-2-Yl]oxy-5-Azanyl-2-[(2s,3r,4s,5s,6r)-4-Azanyl-6-(Hydroxymethyl)-3,5-Bis(Oxidanyl)oxan-2-Yl]oxy-3-Oxidanyl-Cyclohexyl]-4-Azanyl-2-Oxidanyl-
(S)-O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-N1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-D-streptamine
1-N-(L-(-)-4-Amino-2-hydroxybutyryl)kanamycin A
1-N-(L(-)-gamma-Amino-alpha-hydroxybutyryl)kanamycin A
1079316-47-4
108914-65-4
110660-81-6
110660-83-8
111319-93-8
37357-52-1
37517-28-5
38859-32-4
39831-55-5
517A285
6462-EP1441224A2
6462-EP2292612A2
6462-EP2295402A2
6462-EP2301544A1
831A555
84319SGC3C
AB00513828
AB00513828_06
AC1L1YE8
AC1L1ZLB
AC1Q5JTM
AKN
AKOS005383276
AKOS025310105
Ambap149022-22-0
Amicacin
Amiglyde-V
Amiglyde-V (TN)
Amikacillin
amikacin
Amikacin (sulfate)
Amikacin (USP)
Amikacin (USP/INN)
Amikacin [USAN:BAN:INN]
Amikacin [USP:INN:BAN]
Amikacin & Tumor Necrosis Factor
Amikacin Base
Amikacin bis(sulphate)
Amikacin Dihydrate
Amikacin disulfate
Amikacin disulfate salt
Amikacin disulfate salt, potency: 674-786 mug per mg (as amikacin base)
amikacin disulphate
Amikacin for system suitability, European Pharmacopoeia (EP) Reference Standard
Amikacin Inhalation Solution
Amikacin sulfate (JP17/USP)
Amikacin sulfate [USAN:JAN]
Amikacin sulfate [USAN:USP:JAN]
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Amikacin sulfate salt
Amikacin sulfate salt(1:2)
Amikacin sulfate, European Pharmacopoeia (EP) Reference Standard
Amikacin Sulfate, Pharmaceutical Secondary Standard; Certified Reference Material
Amikacin sulfate, United States Pharmacopeia (USP) Reference Standard
Amikacin, Antibiotic for Culture Media Use Only
AMIKACIN, USP
AMIKACIN; BIS(SULFURIC ACID)
Amikacina
Amikacina [INN-Spanish]
amikacine
Amikacine [INN-French]
Amikacinsulfatesalt
Amikacinum
Amikacinum [INN-Latin]
Amikafur
Amikan
Amikavet
Amikin
Amikin (Disulfate)
Amikin (TN)
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Amikin(Disulfate)
Amiklin
Amikozit
Amitrex
Amukin
Antibiotic BB-K 8
ANTIBIOTIC BB-K8
Antibiotic BB-K8 sulfate
API0001444
Arikace
AS-13777
AX8113844
BAY 41-6551
BAY41-6551
BAY416651
BB-K 8
BB-K8
Biklin
Biodacyn
BPBio1_000671
Briclin
BSPBio_000609
C06820
C22H43N5O13
C22H43N5O13.2H2O4S
CA003283
CA009758
CAS-37517-28-5
CHEBI:2637
CHEBI:2638
Chemacin
CHEMBL177
CS-2712
CS-3493
D-Streptamine, O-3-amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-N1-[(2S)-4-amino-2-hydroxy-1-oxobutyl]-2-deoxy-
D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-N(sup 1)-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-
D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-N(sup 1)-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-
D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-N(sup 1)-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-, sulfate (1:2)(salt)
D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-N1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-
D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1,4))-N(sup 1)-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-
D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1.fwdarw.6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1.fwdarw.4))-N1-((2S)-4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-
D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1.fwdarw.6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1.fwdarw.4))-N1-((2S)-4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, sulfate (1:2) (salt)
D00865
D02543
D0Y3MO
DB00479
DR003325
DSSTox_CID_2586
DSSTox_GSID_22586
DSSTox_RID_76645
DTXSID3022586
EINECS 253-538-5
EINECS 254-648-6
Fabianol
H978
HSDB 3583
HY-B0509A
HY-B0509B
J10297
Kaminax
Kancin-Gap
KB-276732
Likacin
LKCWBDHBTVXHDL-RMDFUYIESA-N
LS-146896
LS-146898
Lukadin
MAT2501
MCULE-6148260173
MFCD00167475
MFCD00883675
MFCD11045969
Mikavir
MolPort-000-761-900
MolPort-003-925-527
N1-[(S)-4-Amino-2-hydroxybutyryl]kanamycin A
N6M33094FD
NCGC00093350-02
NCGC00093350-03
NCGC00093350-05
nktr-061
NN-K 8
NSC 177001
NSC177001
O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-D-streptamine
O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->6))-N(3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine
O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->6))-N(3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine sulfate (1:2)
O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-6))-N(sup 3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine
O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-6))-N(sup 3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine sulfate (1:2)
Pierami
Potentox
Prestwick3_000395
s3065
SCHEMBL1649432
SCHEMBL2985
ST24030081
STK039706
Tox21_111201
Tox21_111201_1
UNII-84319SGC3C
UNII-N6M33094FD
W-106531
ZINC8214483

US Patents and Regulatory Information for AMIKACIN SULFATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbott AMIKACIN SULFATE amikacin sulfate INJECTABLE;INJECTION 063265-001 Nov 30, 1994 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
West-ward Pharms Int AMIKACIN SULFATE amikacin sulfate INJECTABLE;INJECTION 063274-001 May 18, 1992 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Hospira AMIKACIN SULFATE amikacin sulfate INJECTABLE;INJECTION 063350-001 Jul 30, 1993 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Fresenius Kabi Usa AMIKACIN SULFATE amikacin sulfate INJECTABLE;INJECTION 205605-001 Dec 9, 2015 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
McKesson
Boehringer Ingelheim
Harvard Business School
Federal Trade Commission
Chubb
Merck
US Department of Justice
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.